Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: A randomized, placebo-controlled study

Diabetic Medicine

Volumn 16, Issue 9, 1999, Pages 755-761

  Willms, Brend ^a   Ruge, D ^a  

^a Bad Lauterberg Diabetes Center   (Germany)

Author keywords

Acarbose; Diet; Metformin; Sulphonylureas; Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; METFORMIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; DIET RESTRICTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; WEIGHT REDUCTION;

ACARBOSE; AGED; BLOOD GLUCOSE; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; FEMALE; FOOD; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PLACEBOS; SULFONYLUREA COMPOUNDS; TRIGLYCERIDES; WEIGHT LOSS;

EID: 0032885589     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.1999.00149.x     Document Type: Article

References (15)

1. Hanefeld M, Fischer S, Schmechel H, Rothe G, Schulze J, Dude H, Schwanebeck U el al Diabetes. Intervention Study. Multi-intervention trial in newly diagnosed NIDDM. Diabetes Care 1991; 14: 308-317.
2. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck V, Schmechel H et al. Risk factors for myocardial infarction and death in newly detected NIDDM. The Diabetes Intervention Study, 11-year follow-up, Diabetologia 1996, 39: 1577-1583.
3. UK Prospective Diabetes Study Croup. UK Prospective Diabetes Study 16. Overview of 6 years therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258.
4. Ravanam A, Jeffery J, Neblawi M. Improvement of glucose-primed intravenous glucose tolerance and correction of acute insulin decrement by glipizide in type II diabetes. Metabolism 1991; 40: 1173-1177.
5. Harrower ADR. Comparison of diabetic control in type 2 (non-insulin-dependent) diabetic patients treated with different sulphonylureas. Curr Med Res Opinin 1985; 9: 676-680.
6. Kilo C, Dudley J, Kalb F Evaluation of safety and efficacy of gliclazide in non-insulin-dependent diabetic patients. Diabetes Res Clin Pract 1991; 14: 79S-82S.
7. Chiasson J-L, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA Crat. The efficacy of acarbose in the trearment of patients with non-insulin-dependent diabetes mellitus: a multicenter controlled clinical trial. Ann Intern Med 1994; 121: 928-935.
8. Baron A, Neumann C. PROTECT interim results: a large muticenter study of parients with type II diabetes. Clin Ther 1907; 19: 282-295.
9. Hottmann JK. Acarbose und Glibenclamid bei Typ II-Diabetes. Münchner Med Wochenscht 1990; 132: 49-51.
10. Spengler M, Hänsel G, Boehme K. Acarbose und Glibenclamid bei Typ II Diabetes. Z Allg Med 1990; 66: 606-610.
11. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarose, glibenclamide or placebo in NIDDM patients: the Essen Study Diabetes Care 1994; 17: 561-566.
12. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarhose, metformin or phicebo in dietary treated NIDDM patients: the Essen-II Study. Am J Med 1997; 103: 483-490.
13. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study VIII. Study design, progress and performance. Diabetologia 1991; 34: 877-890.
14. Holman RR, Cull CA, Turner RC. Glycaemic improvement over one year in a double-Wind trial of acarbose in 1946 NIDDM patients. Diabetologia 1996; 39 (Suppl. 1): A44.
15. Coniff RF, Shapiro JA, Seaton TB, Bray CA, Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 1995; 98: 443-451.